Publications by authors named "Dharshene Shivapatham"
Background: Pediatric acute liver failure (PALF) carries a high mortality without liver transplantation (LT) in children. Liver transplantation, though lifesaving, is limited by timely donor organ availability, the risks of major surgery and complications of life-long immunosuppression. Hepatocyte transplantation (HT) improves synthetic and detoxification functions in small animal models.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on a new immunotherapy approach called T4, designed to treat locally advanced/recurrent head and neck squamous cell carcinoma (HNSCC) by targeting upregulated ErbB proteins in tumor cells.
- This phase 1 trial involved injecting engineered CAR T-cells directly into tumors, with doses provided in escalating amounts, and showcased that these T-cells could be successfully manufactured from patient blood without toxic effects.
- In terms of results, the treatment showed manageable side effects (mostly mild) and demonstrated localized persistence of T-cells in the tumor site, however, it did not halt rapid tumor progression in patients.
The HAVEN study-hydroxychloroquine in ANCA vasculitis evaluation-a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan.
Trials
April 2023
Background: Patients with non-severe ANCA-associated vasculitis (AAV) are often prescribed immunosuppressive medications that are associated with severe side effects and a reduced quality of life. There is an unmet need for safer effective treatments for these patients. Hydroxychloroquine is being explored due to its effect in similar autoimmune conditions such as systemic lupus erythematosus.
View Article and Find Full Text PDFTrial Design: We present a study protocol for a multi-centre, randomised, double-blind, parallel-group, placebo-controlled trial that seeks to test the feasibility, acceptability and effectiveness of a 52-week period of treatment with the first-in-class co-stimulatory blocker abatacept for preventing or delaying the onset of inflammatory arthritis.
Methods: The study aimed to recruit 206 male or female subjects from the secondary care hospital setting across the UK and the Netherlands. Participants who were at least 18 years old, who reported inflammatory sounding joint pain (clinically suspicious arthralgia) and who were found to be positive for serum autoantibodies associated with rheumatoid arthritis (RA) were eligible for enrolment.